The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Acces GIR
Login
Català
Castellano
English
The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Search
Most popular
COL·LABORA
Menu
English
Català
Español
Home
Àrees Recerca
HEALTH SERVICES RESEARCH
EMAP
EMAP
Estudis en Medicaments en Atenció Primària (EMAP)
Group leader
Rosa Morros Pedrós
rmorros@idiapjgol.org
Presentation
Team
Publications
Projects
News
Presentation
Team
Publications
Projects
News
Projects
Group projects
Oral and Neuro-Penetrative Alternative Antibiotics for Patients with Syphilis
Principal investigators:
Silvia Fernández García, Rosa Morros Pedrós
Code:
9F22/004
Start year:
2022
Funders:
Fundació Lluita contra la Sida. Hº Trias i Pujol
Riscos de les interaccions farmacològiques dels anticoagulants orals directes: esdeveniments trombòtics i hemorràgics que són motiu d’ingrés hospitalari a Catalunya
Principal investigators:
Rosa Morros Pedrós
Code:
4R22/341
Start year:
2022
Funders:
Generalitat Catalunya
Premi Trajectòria AP Rosa Morros Premis ICS 2023
Principal investigators:
Rosa Morros Pedrós
Code:
7Z-0-00044-23
Start year:
2023
Funders:
ICS - Institut Català de la Salut
Implementation of Out-of-Hospital administration of the Long-Actin combination cabotegravir+rilpivirine as an optional therapy in HIV Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction. The HOLA Study
Principal investigators:
Silvia Fernández García, Rosa Morros Pedrós
Code:
9F-0-00001-25
Start year:
2025
Funders:
Fundació Lluita contra la Sida. Hº Trias i Pujol
Association between previous biologic therapy exposure and incidence and severity of life-threating infections in patients with rheumatoid arthritis and psoriasis. A population-based cohort study
Principal investigators:
Rosa Morros Pedrós
Code:
4RNC-0-00007-25
Start year:
2025
Funders:
Consoricio Centro de Investigación Biomédica en RED (CIBER)
Anterior
1
2
3
4
5
6
…
11
Següent
Board of Trustees
Collaborators
Accreditations